Quantcast
Home » Topics » exelixis inc

Exelixis thyroid cancer drug meets late-stage goal

(Reuters) – Exelixis Inc said a late-stage trial of its experimental thyroid cancer drug met the main goal of improving survival of patients without disease progression, compared with a dummy drug. The drug cabozantinib significantly improved median progression-free survival (PFS) by 7.2 months compared with a placebo. The median PFS…

Google+